Marshall Islands vs Mexico: Prevalence rate of hypertension in adults aged 30-79
Marshall Islands
31.9
in 2019
Mexico
32.1
in 2019
Marshall Islands rank
149th
Mexico rank
148th
Prevalence rate of hypertension in adults aged 30-79 over time
- Marshall Islands
- Mexico
How they compare
Mexico currently reports 32.1 against 31.9 in Marshall Islands, a difference of 0.2.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Marshall Islands ahead.
Marshall Islands ranks 149th and Mexico ranks 148th of 194 countries.
Mexico has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Marshall Islands | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 28.58 | 31.63 | 3.05 | Mexico |
| 2000s | 28.82 | 34.72 | 5.9 | Mexico |
| 2010s | 31.19 | 33.68 | 2.49 | Mexico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in adults aged 30-79, Marshall Islands or Mexico?
- Mexico, at 32.1 against 31.9 in Marshall Islands as of 2019.
- What is the difference in prevalence rate of hypertension in adults aged 30-79 between Marshall Islands and Mexico?
- 0.2, with Mexico ahead.
- How many years of comparable data are there for Marshall Islands and Mexico?
- 30 years are reported by both, from 1990 to 2019.
- How do Marshall Islands and Mexico rank globally for prevalence rate of hypertension in adults aged 30-79?
- Marshall Islands ranks 149th and Mexico ranks 148th of 194 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in adults aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of the population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.